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Due to an error at the publishers, the following paper was
printed in the March, 1991 issue with numerous errors in the
Summary and in the text. Reprints of a correct version of the
paper may be obtained from: Dr P.R. Twentyman, MRC
Clinical Oncology and Radiotherapeutics Unit, Hills Road,
Cambridge CB2 2QH, UK.
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Retention of activity by selected anthracycfines in a multidrug resistant
human large cell lung carcinoma line without P-glycoprotein
hyperexpression
H.M. Coley*, P. Workman & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
Summary A subline (COR-L23/R) of the human large cell lung line COR-L23, derived by in vitro exposure
to doxorubicin, exhibits an unusual multidrug resistant (MDR) phenotype. This subline shows cross-resistance
to daunorubicin, vincristine, colchicine and etoposide but does not express P-glycoprotein. Interestingly,
COR-L23/R shows little or no resistance to a range of structurally-modified analogues of doxorubicin
comprising 9-alkyl and/or sugar modified anthracyclines. We have previously identified these same compounds
as effective agents against P-glycoprotein-positive MDR cell lines. In contrast to typical MDR cell lines.
COR-L23/R shows only minimal chemosensitisation by verapamil and no collateral sensitivity to verapamil.
Compared to the parental cell line, COR-L23/R displays reduced accumulation of doxorubicin and
daunorubicin. Accumulation defects were apparent only after 0.5-1 h of incubation of cells with these agents.
The rate of daunorubicin efflux was shown to be enhanced in COR-L23/R and this efflux was demonstrated to
be energy-dependent. The use of anthracyclines which retain activity in MDR cells thus appears to be a valid
approach for the circumvention of MDR, not only in cells which express P-glycoprotein, but also where
defective drug accumulation is due to other mechanisms possibly involving an alternative multidrug trans-
porter.
In the paper entitled 'The clinical effects of prolonged treat-
ment of patients with advanced cancer with lose-dose sub-
cutaneous interleukin-2; (volume 63, pp. 275-278, 1991) the
title should read 'The clinical effects of prolonged treatment
of patients with advanced cancer with low-dose subcutaneous
interleukin-2'.
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